Antibacterial compounds

Patent metadata

Field	Value
Publication number	US-9428474-B2
Application number	US-201314654186-A
Country	US
Kind code	B2
Filing date	Dec 20, 2013
Priority date	Dec 21, 2012
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

The present invention relates to the following compounds for use in the treatment of a bacterial infection

wherein the integers are as defined in the description. The invention also relates to compounds for use as medicaments, pharmaceutical compositions and some novel compounds.

First claim

The invention claimed is:

1. A compound of formula (I):

wherein
R 1 , R 2 , R 3 and R 4 each independently are selected from the group consisting of: hydrogen, halo, —CN, R t1 , —O—R t2 , —C(O)N(R t3 )(R t4 ), —SO 2 R t5 , —N(H)SO 2 R t6 , —N(R t7 )(R t8 ), aryl and heterocyclic group wherein said aryl and said heterocyclic group optionally substituted by one or more substituents selected from halo and C 1-6 alkyl;
R t1 , R t2 , R t3 , R t4 , R t5 , R t6 , R t7 and R t8 independently are hydrogen or C 1-6 alkyl wherein said C 1-6 alkyl is optionally substituted by one or more halo atoms, or, R t3 and R t4 and/or R t7 and R t8 may be linked together with the nitrogen atom to which they are attached to form a 3- to 7-membered ring, optionally containing one to three additional heteroatoms and optionally contain one to three double bonds;
Z x is O or S;
X is S or O;
ring A is either:

R x is hydrogen or C 1-6 alkyl wherein said C 1-6 alkyl is optionally substituted by one or more substituents selected from the group consisting of fluoro, —CN, —OR x1 , and —C(O)R x2 ;
R x1 and R x2 independently are hydrogen or C 1-6 alkyl;
R y3 independently is hydrogen, halo, C 1-6 alkyl, —OR y4 , —C(O)—R y5 or —CH 2 —OR y6 ;
R y4 , R y5 and R y6 independently are hydrogen or C 1-6 alkyl;
wherein R y1 is fluoro, chloro, C 1-6 alkyl, —OH, —C(O)R y5 or —CH 2 —OR y6 ; and R y2 is —OH, C 1-6 alkyl, —C(O)R y5 or —CH 2 —OR y6
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound claimed in claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating a bacterial infection, comprising: (i) administering to a patient suffering from a bacterial infection a compound as claimed in claim 1 ; and (ii) administering another therapeutic agent for use in the treatment of a bacterial infection.

4. A method as claimed in claim 3 , wherein the bacterial infection is a mycobacterial infection.

5. A method as claimed in claim 4 , wherein the mycobacterial infection is Mycobacterium tuberculosis.

6. A process for preparing a composition as claimed in claim 2 , wherein a therapeutically active amount of the compound is intimately mixed with a pharmaceutically acceptable carrier.

Assignees

• Janssen Sciences Ireland Uc

Inventors

• Guillemont Jérôme Émile Georges
• Motte Magali Madeleine Simone
• Koul Anil
• Lounis Nacer

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/06

  for tuberculosis · CPC title

• C07D277/82 Primary

  Nitrogen atoms · CPC title

• A61K31/428

  condensed with carbocyclic rings · CPC title

• C07D277/62 Primary

  Benzothiazoles · CPC title